Dr. Larsen is acting Deputy Director of the Biomedical Advanced Research Development Authority (BARDA). In that role, he oversees a $2.8B fund for the development and procurement of medical products for use during public health emergencies. From 2014-2016, Joe served as the Deputy Director of BARDA’s Chemical, Biological, Radiological, and Nuclear Medical Countermeasure Division. He is also the BARDA lead for the Obama Administration’s Initiative on combating antibiotic resistant bacteria and has chaired intergovernmental working groups on research and development and economic incentives for antibacterial drug development. Previously Dr. Larsen served as Chief of the Broad Spectrum Antimicrobials program at BARDA. The goal of BARDA’s Broad Spectrum Antimicrobials program is to develop additional antimicrobial treatment options needed to counter the growing threat of antimicrobial resistance. In that role, he oversaw a portfolio of approximately $1.2B in programs that support the development of novel antibacterial and antiviral drugs. Dr. Larsen also serves as the BARDA representative on the U.S. Transatlantic Task Force on Antimicrobial Resistance. Previously, Dr. Larsen served as a Senior Science and Technology Manager at the Joint Science and Technology Office for Chemical and Biological Defense (JSTO-CBDP) within the Defense Threat Reduction Agency (DTRA). There, he managed a ~$50M applied research program aimed at the development of medical therapeutics against viral, bacterial, and toxin threat agents. From 2005-2006, Dr. Larsen was an American Association for the Advancement of Science (AAAS) fellow at the Department of Homeland Security. There, he managed University based research programs aimed at the development enhanced food safety detection systems and medical countermeasures for agricultural threat agents. Joe was a 2005 National Academy of Science Christine Mirzayan fellow with the Board of Life Sciences. Dr. Larsen received his PhD in Microbiology from the Uniformed Services University of the Health Sciences and his BA with honors from the University of Kansas.
Dr. Larsen will be speaking at World Anti-Microbial Resistance Congress USA 2016 about ‘Combating Antibiotic Resistant Bacteria (CARB) Biopharmaceutical Accelerator Initiative’. This session will cover novel public-private partnership to support R&D and move drugs, vaccines, and diagnostics into pre-clinical development, providing financial, business, and drug development guidance, and how the accelerator is different from other public private partnerships. To hear from Dr. Joseph Larsen and other industry experts, attend World Anti-Microbial Resistance Congress USA 2016 held September 8-9 in Washington, DC.